Affordable Access

Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo.

Authors
Type
Published Article
Journal
Journal of the American Academy of Dermatology
0190-9622
Publisher
Elsevier
Publication Date
Volume
53
Issue
4
Pages
616–622
Identifiers
PMID: 16198781
Source
Medline

Abstract

Infliximab was extremely effective and well tolerated in this group of patients with severe, recalcitrant psoriasis. Thirty-nine of 52 patients have continued receiving treatment for a median duration of 25 months with excellent disease control. Infliximab can provide control of extensive psoriasis with continued intermittent infusions.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments